Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
Macular telangiectasia type 2 (MacTel) is a rare, progressive retinal disease characterized by neurodegenerative changes, localized retinal degeneration, and alterations in the retinal vasculature. It usually presents bilaterally and leads to gradual central vision loss, and its early signs and symptoms are subtle and nonspecific. In this program, expert faculty discuss recent innovations in approved therapy for this condition and opportunities for early detection and diagnosis.
This educational activity is an archive of the live virtual symposium held on August 2, 2025.
Target Audience
This educational activity is directed toward retina specialists, comprehensive ophthalmologists, and other eye care professionals who treat patients with MacTel.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the limitations of anti-VEGF intravitreal injection therapies in the management of MacTel
- Evaluate emerging evidence supporting the use of novel therapies in the management of MacTel
- Integrate current evidence-based interventions for MacTel into clinical practice to optimize disease outcomes
- Apply advanced diagnostic and therapeutic interventions to the management of MacTel
Dante Pieramici, MD, FASRS
Medical Director, Clinical Research, California Retina Consultants
Director, California Retina Research Foundation
Partner, California Retina Consultants/Retina Consultants of America
Santa Barbara, CA
Disclosures: Advisory Board: Perceive Bio; Consultant: 4DMT, Adverum, Eyepoint, Genentech/Roche, Neurotech, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Samsung, Unity; Research Funding: 4DMT, Adverum, Eyepoint, Genentech/Roche, Novartis, Ocular, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Unity.
Dean Eliott, MD
Stelios Evangelos Gragoudas Professor of Ophthalmology
Director Emeritus, Retina Service
Director, Surgical Retina Fellowship
Harvard Medical School
Massachusetts Eye and Ear
Boston, MA
Disclosures: Consultant, Stockholder: Alcon, Aldeyra Therapeutics, Ingenia Therapeutics, Neurotech, Pykus Therapeutics, RetMap; DSMB Member: Aviceda, Clearside Biomedical, EyeBio, Ocular Therapeutix; Research Grants: Neurotech; Patent Royalties: Aldeyra Therapeutics.
Robin A. Vora, MD
Chair of Ophthalmology
The Permanente Medical Group, Inc
Oakland, CA
Disclosures: Advisor, Consultant, Speaker: Adverum, Astellas, EyePoint, Genentech/Roche, Kyoto D&D, Outlook, Regeneron.
Charles C. Wykoff, MD, PhD, FASRS
Director of Research, Retina Consultants of Texas
Chairman, Research and Clinical Trials, Retina Consultants of America
Houston, TX
Disclosures: Consultant/Honoraria: 4DMT, AbbVie, Acuta, ADARx, Adverum, Alcon, Alimera, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis, Arrowhead, Ascidian, Astellas, Aviceda, Bausch + Lomb, Bayer, BioCryst, Bionic Vision, Boehringer Ingelheim, Chengdu Kanghong, Curacle, Emmecell, Eyebiotech, EyePoint, Genentech, InGel, Janssen, Kiora, Kodiak, Kowa, Nanoscope, Neurotech, NGM, Novartis, Oak Bay Bio, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Opus, Osanni, Oxular, Palatin, Perceive Bio, Perfuse, Ray, Regeneron, Regenxbio, RetinAI, Roche, Samsung Bioepis, Sandoz, Sanofi, Santen, Skyline, Stealth, Sylentis, TCG Crossover, THEA, Therini, VH401, Visgenx, Zeiss; Research Grants: 4DMT, AbbVie, Adverum, AffaMed, Alexion, Alimera, Allgenesis, Amgen, Annexin, Annexon, Apellis, Ascidian, AsclepiX, Astellas, Aviceda, Avirmax, Bayer, Boehringer Ingelheim, Chengdu Origen, Clearside, Curacle, Eluminex, Eyebiotech, EyePoint, Genentech, IONIS, iRenix, Janssen, Kalaris, Kodiak, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Ollin, Opthea, Outlook Therapeutics, Oxular, Oxurion, Perceive Bio, Pykus, Regeneron, Regenxbio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline, VH401; Stock Options (not owner) From Private For-Profit Entities: InGel, Ollin, ONL, Osanni, Panther, TissueGen, Visgenx, Vitranu.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here